BioSpace News Archive

Movement Orthopedics: A Great Alternative To The ER For Orthopedic Injuries

Funding to support expansion of ion channel screening capabilities and continued research into potential drugs for auto-immune diseases

Do you find your dog cowering in a corner after a clap of thunder? Does he pace, drool or whine when there is a storm pending? If so, your pooch may be suffering from storm phobia.

STRO-001 Ongoing Phase 1 Trial in Myeloma and Lymphoma with Initial Safety Data Expected Mid-2019

Chondrogenix will use Mogrify’s data-driven conversion platform to generate a safe, efficient and scalable source of cartilage cells for the treatment of osteoarthritis

Throughout April, New Yorkers will participate in activities across the state to build awareness for organ, eye and tissue donation.

AngioDynamics, Inc. announced that the United States Food and Drug Administration approved the Company’s investigational device exemption application for its NanoKnife® Irreversible Electroporation “Direct IRE Cancer Treatment” clinical study.

Aerie Pharmaceuticals, Inc. announced the appointment of Gianluca Corbinelli as Chief Commercial Officer - Europe, reporting to Thomas Mitro, Aerie’s President and Chief Operating Officer.

Acquisition of IFM Therapeutics subsidiary gives Novartis full rights to one clinical and two pre-clinical NLRP3 antagonist programs

On February 12th, 2019, it was announced that Moberg Pharma AB has entered into agreement with RoundTable Healthcare Partners and Signet Healthcare Partners to divest the entire commercial operation and that the Company intends to redeem its outstanding bonds 2016/2021 with ISIN SE0007953989 in connection with closing of the transaction.